You can buy or sell EVLO and other stocks, options, ETFs, and crypto commission-free!
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Its product candidates are single strains of microbes, selected for defined pharmacological properties. Read More The firm currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Expected May 30, Pre-Market